News

Breaking: Inrebic (Fedratinib) approved for Myelofibrosis! This becomes the first FDA approved drug for an MPN in nearly a decade

It is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).

ASH Awards the 2019 William Dameshek Prize

The American Society of Hematology presented Emmanuelle Passegué, Ph.D., of Columbia University Irving Medical Center in New York City with the 2019 William Dameshek Prize for her outstanding contribution to the field of hematology.

CPI-0610 Demonstrates Activity in MF Patients After Ruxolitinib Failure

A researcher at Mt. Sinai in this video discusses observations from their clinical trial with the drug CPI-0610.

The MPN Familial Study

We know that myeloproliferative neoplasms may occasionally run in families, but what we don't know is why. The Fleischman Lab, headed by Dr. Angela Fleischman, MD. PhD. in Irvine, CA is seeking to answer that question.

The Advancement of Targeted Therapy

Since the development of the JAK1/2 inhibitor ruxolitinib, our understanding of MPNs has come a long way. Researchers Bing Li, Raajit K. Rampal, and Zhijian Xiao document the targeted therapies currently in various stages of development,

Promising Results of New AACR Study

Researchers at the American Association for Cancer Research recently published an article highlighting the restoration of T-cells specific to fighting the CALR mutation in MPN patients.

How does MDM2 inhibition work to treat MPNs?

Renowned experts Dr. Srdan Verstovsek and Dr. Jason Gotlib discuss MDM2 inhibition as an avenue for the treatment of MPNs and share information on an upcoming MDM2 clinical trial.

Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in MF patients

Positive safety and early efficacy clinical data was proven during Promedior's Phase 2 study of PRM-151 in MF patients

Imago BioSciences to Expand Clinical Trial of IMG-7829 for MF Patients

"IMG-7289 has shown tremendous promise to be a meaningful treatment option for myelofibrosis patients, and these data support our clinical program," said Hugh Young Rienhoff, CEO of Imago BioSciences

Possible New Myelofibrosis Drug Gets Fast Tracked by the FDA

Sierra Oncology announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis.

MPN Updates from ASCO 2019

This yearly meeting brings together not only oncology professionals from all disciplines but also includes pharmaceutical companies, advocacy groups and more to discuss the latest updates in cancer research and treatment.

Researchers at Mount Sinai Investigate a Novel Class of Drugs for MPN Patients

Researchers in The Tisch Cancer Institute's Myeloproliferative Neoplasms (MPN) Program at Mount Sinai is investing a novel class of drugs for MPN patients.

MPNRF Celebrates 1st Annual Founder's Day

The MPN Research Foundation is celebrating our first annual Founder's Day in memory of Robert (Bob) Rosen, the person who started it all almost 20 years ago. Today, May 6th is particularly special as it was Bob's birthday, and we look forward to celebrating his legacy on this day for years to come.

Clinical Trial for AVID200 Doses First MF Patient

A TGF-Beta inhibitor - AVID 200 - is joining the race for new therapies for myeloproliferative neoplasms.

MPN Research Foundation's Patient Registry Featured in Cure Today

In an article published by CURE Magazine, Robyn M. Scherber, M.D., M.P.H, assistant professor of medicine in the Department of Hematology and Oncology at UT Health San Antonio MD Anderson Cancer Center, and co-author Michelle Woehrle, the executive director of the MPN Research Foundation sat down to discuss the newest findings from MPNRF's patient registry, myMPN.